HOME ABOUT CONTACT AVAILABLE ISSUES SUBSCRIBE MEDIA & ADS
LATEST UPDATES » Vol 22, No 05, May 2018 – Dental health - The root to good health       » Drugs to watch 2018       » Dragonfly-inspired nano coating kills bacteria upon contact       » New compound improves stroke recovery in monkeys and mice       » Cancer stem cell therapy breakthrough       » Draft genome of tea plant sequenced      
BIOBOARD - SINGAPORE
Cholesterol beats coronaviruses, Avian flu and Swine flu
Amid fears of a global coronavirus outbreak, Viroblock SA, a Swiss start-up, presented new data at the International Conference on Prevention & Infection Control (ICPIC) 2013 in Geneva, showing that their respiratory face mask containing proprietary novel cholesterol depletion technology traps and kills over 99.997% of human corona viruses, 99.999% of H5N1 flu viruses (avian flu) and 99.9995% of H1N1 flu viruses (swine flu) on pass through air. Aimed at helping protect people from these respiratory pathogens, the mask is up to one hundred times more effective than a similar mask without Viroblock technology. The company will now start direct sales in Switzerland and is looking for distributors in Singapore where the local authorities have stepped up their operational readiness for a potential outbreak.

“Aerobiology tests for face-masks simulate real life situations, in which the user is exposed to viruses coming in. The mask helps prevent transmission from and to the person wearing the mask,” commented Dr. Thierry Pelet, CSO at Viroblock. “The stringent testing demonstrates the efficacy and speed at which the cholesterol depletion technology works”.

Aerobiology tests, carried out in high security laboratories, create a mist of viruses on the outside of the mask, a pump is used to draw air and viruses through the mask, and finally testing for live virus occurs on the inside of the mask.

“We believe that our protective face-mask can help protect healthcare, agriculture and security workers effectively, with added advantages of comfort of wear and easy identification,” said Dr. Jamie Paterson, CEO of Viroblock.

Viroblock SA is a CTI Certified Swiss start-up located in Geneva, Switzerland. Founded in 2006 and supported mainly by Swiss investors, the company is focused on developing a unique anti-viral technology based on cholesterol depletion. Viroblock's first product is an anti-viral face-mask and other air filtration products are planned.

Click here for the complete issue.

NEWS CRUNCH  
news Shire, Microsoft and EURORDIS form Global Commission to accelerate time to diagnosis for children with rare diseases
news EmTech Asia explores future of life, humanity and economy
news Biology of Ageing II - Impactful Interventions
PR NEWSWIRE  
Asia Pacific Biotech News
EDITORS' CHOICE  
COLUMNS  
Subscribe to APBN E-Newsletter
Find us under 'Others' option to receive APBN e-newsletters thrice a month!

APBN Editorial Calendar 2018
January:
Obesity / Outlook for 2018
February:
Searching for the fountain of youth
March:
Women in Science - Making a difference
April:
Digestive health in the 21st century - Trust your guts
May:
Dental health - The root to good health
June:
Oncology / Biotech landscape in APAC
July:
Water management / Vaccination
August:
Regenerative medicine / Biotech start ups
September:
Digital healthcare / 3D printing
October:
Bones / Breast cancer
November:
Liver health / Top science research nations & institutions
December:
AIDS / Breakthrough of the year/Emerging trends
Editorial calendar is subjected to changes.
MAGAZINE TAGS
About Us
Events
Available issues
Editorial Board
Letters to Editor
Instructions to Authors
Advertise with Us
CONTACT
World Scientific Publishing Co. Pte. Ltd.
5 Toh Tuck Link, Singapore 596224
Tel: 65-6466-5775
Fax: 65-6467-7667
» For Editorial Enquiries:
   biotech_edit@wspc.com or Ms Lim Guan Yu
» For Subscriptions, Advertisements &
   Media Partnerships Enquiries:
   biotech_ad@wspc.com
Copyright© 2018 World Scientific Publishing Co Pte Ltd  •  Privacy Policy